Suppr超能文献

在药物开发和精准医学中应用的人源仿生肝微生理系统。

Human biomimetic liver microphysiology systems in drug development and precision medicine.

机构信息

University of Pittsburgh Drug Discovery Institute, University of Pittsburgh, Pittsburgh, PA, USA.

Department of Computational and Systems Biology, University of Pittsburgh, Pittsburgh, PA, USA.

出版信息

Nat Rev Gastroenterol Hepatol. 2021 Apr;18(4):252-268. doi: 10.1038/s41575-020-00386-1. Epub 2020 Dec 17.

Abstract

Microphysiology systems (MPS), also called organs-on-chips and tissue chips, are miniaturized functional units of organs constructed with multiple cell types under a variety of physical and biochemical environmental cues that complement animal models as part of a new paradigm of drug discovery and development. Biomimetic human liver MPS have evolved from simpler 2D cell models, spheroids and organoids to address the increasing need to understand patient-specific mechanisms of complex and rare diseases, the response to therapeutic treatments, and the absorption, distribution, metabolism, excretion and toxicity of potential therapeutics. The parallel development and application of transdisciplinary technologies, including microfluidic devices, bioprinting, engineered matrix materials, defined physiological and pathophysiological media, patient-derived primary cells, and pluripotent stem cells as well as synthetic biology to engineer cell genes and functions, have created the potential to produce patient-specific, biomimetic MPS for detailed mechanistic studies. It is projected that success in the development and maturation of patient-derived MPS with known genotypes and fully matured adult phenotypes will lead to advanced applications in precision medicine. In this Review, we examine human biomimetic liver MPS that are designed to recapitulate the liver acinus structure and functions to enhance our knowledge of the mechanisms of disease progression and of the absorption, distribution, metabolism, excretion and toxicity of therapeutic candidates and drugs as well as to evaluate their mechanisms of action and their application in precision medicine and preclinical trials.

摘要

微生理系统(MPS),也称为器官芯片和组织芯片,是构建在多种物理和生化环境线索下的多个细胞类型的微型化器官功能单元,作为药物发现和开发新模式的一部分,补充了动物模型。仿生人类肝脏 MPS 已经从更简单的 2D 细胞模型、球体和类器官发展而来,以满足越来越多的需求,以了解复杂和罕见疾病的患者特异性机制、对治疗方法的反应以及潜在治疗药物的吸收、分布、代谢、排泄和毒性。包括微流控设备、生物打印、工程基质材料、定义的生理和病理生理介质、患者来源的原代细胞和多能干细胞以及合成生物学在内的跨学科技术的平行发展和应用,为构建患者特异性、仿生 MPS 以进行详细的机制研究创造了潜力。预计在开发和成熟具有已知基因型和完全成熟成人表型的患者衍生 MPS 方面的成功将导致在精准医学中的先进应用。在这篇综述中,我们研究了旨在重现肝脏腺泡结构和功能的仿生人类肝脏 MPS,以增强我们对疾病进展机制以及治疗候选物和药物的吸收、分布、代谢、排泄和毒性的了解,并评估它们的作用机制及其在精准医学和临床前试验中的应用。

相似文献

4
Developing Liver Microphysiological Systems for Biomedical Applications.用于生物医学应用的肝脏微生理系统的开发。
Adv Healthc Mater. 2024 Aug;13(21):e2302217. doi: 10.1002/adhm.202302217. Epub 2023 Nov 27.
7
Next generation human skin constructs as advanced tools for drug development.下一代人造皮肤构建体作为药物开发的先进工具。
Exp Biol Med (Maywood). 2017 Nov;242(17):1657-1668. doi: 10.1177/1535370217712690. Epub 2017 Jun 7.
9
Organs-on-a-Chip.器官芯片。
Adv Exp Med Biol. 2020;1230:27-42. doi: 10.1007/978-3-030-36588-2_3.

引用本文的文献

5
Cell therapy for end-stage liver disease: Current state and clinical challenge.终末期肝病的细胞治疗:现状与临床挑战
Chin Med J (Engl). 2024 Dec 5;137(23):2808-2820. doi: 10.1097/CM9.0000000000003332. Epub 2024 Nov 18.
9
Biomimetic Liver Lobules from Multi-Compartmental Microfluidics.仿生多腔室微流控肝小叶
Adv Sci (Weinh). 2024 Nov;11(42):e2406573. doi: 10.1002/advs.202406573. Epub 2024 Sep 19.

本文引用的文献

3
Organs-on-chips: into the next decade.芯片器官:迈向新的十年。
Nat Rev Drug Discov. 2021 May;20(5):345-361. doi: 10.1038/s41573-020-0079-3. Epub 2020 Sep 10.
5
Substrate stiffness regulates primary hepatocyte functions.底物硬度调节原代肝细胞功能。
RSC Adv. 2015;5(99):80956-80966. doi: 10.1039/C5RA15208A. Epub 2015 Sep 14.
6
Engineering Microphysiological Immune System Responses on Chips.工程化芯片上的微生理免疫系统反应
Trends Biotechnol. 2020 Aug;38(8):857-872. doi: 10.1016/j.tibtech.2020.01.003. Epub 2020 Feb 18.
7
FDA rejects NASH drug.美国食品药品监督管理局拒绝了非酒精性脂肪性肝炎药物。
Nat Rev Drug Discov. 2020 Aug;19(8):501. doi: 10.1038/d41573-020-00126-9.
8
Human Pluripotent Stem Cell-Derived Organoids as Models of Liver Disease.人多能干细胞衍生类器官作为肝脏疾病模型。
Gastroenterology. 2020 Oct;159(4):1471-1486.e12. doi: 10.1053/j.gastro.2020.06.010. Epub 2020 Jun 15.
9
Tackling rare diseases: Clinical trials on chips.攻克罕见病:芯片上的临床试验。
Exp Biol Med (Maywood). 2020 Jul;245(13):1155-1162. doi: 10.1177/1535370220924743. Epub 2020 May 12.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验